ATE476652T1 - Quantitative assays für ras p21 in körperflüssigkeiten - Google Patents

Quantitative assays für ras p21 in körperflüssigkeiten

Info

Publication number
ATE476652T1
ATE476652T1 AT06785512T AT06785512T ATE476652T1 AT E476652 T1 ATE476652 T1 AT E476652T1 AT 06785512 T AT06785512 T AT 06785512T AT 06785512 T AT06785512 T AT 06785512T AT E476652 T1 ATE476652 T1 AT E476652T1
Authority
AT
Austria
Prior art keywords
preneoplastic
ras
total ras
patient
monitor
Prior art date
Application number
AT06785512T
Other languages
English (en)
Inventor
Walter Carney
Peter Hamer
Karen Pierce
Sheryl Brown-Shimer
Original Assignee
Siemens Healthcare Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics filed Critical Siemens Healthcare Diagnostics
Application granted granted Critical
Publication of ATE476652T1 publication Critical patent/ATE476652T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Devices For Use In Laboratory Experiments (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
AT06785512T 2005-06-23 2006-06-23 Quantitative assays für ras p21 in körperflüssigkeiten ATE476652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69408205P 2005-06-23 2005-06-23
PCT/US2006/024647 WO2007002505A1 (en) 2005-06-23 2006-06-23 Quantitative assays for ras p21 in body fluids

Publications (1)

Publication Number Publication Date
ATE476652T1 true ATE476652T1 (de) 2010-08-15

Family

ID=37595465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06785512T ATE476652T1 (de) 2005-06-23 2006-06-23 Quantitative assays für ras p21 in körperflüssigkeiten

Country Status (8)

Country Link
US (2) US20100167324A1 (de)
EP (1) EP1893997B1 (de)
JP (1) JP4693902B2 (de)
AT (1) ATE476652T1 (de)
CA (1) CA2612693C (de)
DE (1) DE602006015957D1 (de)
ES (1) ES2349660T3 (de)
WO (1) WO2007002505A1 (de)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200764B1 (en) * 1985-01-29 2001-03-13 Bayer Corporation Detection, quantitation and classification of ras proteins in body fluids and tissues
US5443956A (en) * 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US5081230A (en) * 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
EP0206065A3 (de) * 1985-06-27 1989-04-19 James R. Feramisco Verfahren zum Nachweis von oncogenischen und proto-oncogenischen Proteinen in extrazelligen biologischen Flüssigkeiten
IL79755A0 (en) * 1985-08-21 1986-11-30 Oncogene Science Inc Immunoassay for detection of ras encoded protein
US5262523A (en) * 1987-07-08 1993-11-16 Oncogene Science, Inc. Antibodies reactive with normal and oncogenic forms of the ras p21 protein
EP0411018B1 (de) * 1988-04-22 1997-06-04 Oncogene Science, Inc. Nachweis, quantifizierung und klassifizierung von ras-proteinen in körperflüssigkeiten und geweben
US6165734A (en) * 1995-12-12 2000-12-26 Applied Spectral Imaging Ltd. In-situ method of analyzing cells
WO1999041613A1 (en) * 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
CA2388517A1 (en) * 1999-11-16 2001-05-25 The General Hospital Corporation Compositions and methods for regulating tumor-associated antigen expression
US6489128B1 (en) * 2000-01-24 2002-12-03 Rhode Island Hospital, A Lifespan Partner Methods for detecting cancer of the central nervous system
KR20040081420A (ko) * 2001-10-16 2004-09-21 마운트 시나이 하스피틀 코포레이션 난소암의 검출 방법
ATE441107T1 (de) * 2002-03-01 2009-09-15 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von kírperflüssigkeiten
WO2005013804A2 (en) * 2003-08-05 2005-02-17 Euro-Celtique S.A. ErbB RECEPTOR METHODS AND KITS FOR MONITORING CHEMOTHERAPY RESISTANCE
EP1682126B1 (de) * 2003-10-16 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Substituierte benzazole und ihre verwendung als raf-kinase-hemmer

Also Published As

Publication number Publication date
EP1893997B1 (de) 2010-08-04
WO2007002505A1 (en) 2007-01-04
US20140093890A1 (en) 2014-04-03
DE602006015957D1 (de) 2010-09-16
JP4693902B2 (ja) 2011-06-01
EP1893997A1 (de) 2008-03-05
CA2612693A1 (en) 2007-01-04
CA2612693C (en) 2012-05-08
US20100167324A1 (en) 2010-07-01
ES2349660T3 (es) 2011-01-10
EP1893997A4 (de) 2009-02-18
JP2008547027A (ja) 2008-12-25

Similar Documents

Publication Publication Date Title
ATE493652T1 (de) Quantitative assays für pdgfr-beta- in körperflüssigkeiten
Bahadır et al. Applications of electrochemical immunosensors for early clinical diagnostics
Pin et al. The role of proteomics in prostate cancer research: biomarker discovery and validation
ATE554386T1 (de) Verbesserte immunoassayverfahren
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
DE602006011896D1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
BRPI0412725A (pt) marcadores para detecção de cáncer gástrico
RU2014111182A (ru) Способ обнаружения злокачественных опухолей
RU2017126701A (ru) Способ детекции нуклеосом, содержащих нуклеотиды
WO2009019230A3 (en) Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease
DE69928809D1 (de) Differentielle diagnose von neurodegeneration
BR112015011359A2 (pt) método para indicar uma presença ou não presença de câncer de próstata agressivo
BRPI0311233B8 (pt) métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
WO2006081473A8 (en) Methods for diagnosis and prognosis of epithelial cancers
WO2004058044A3 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
ATE445160T1 (de) Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
CY1113403T1 (el) Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
WO2008069975A3 (en) Methods of using f-spondin as a biomarker for cartilage degenerative conditions
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
EP1838867A4 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
WO2010084327A3 (en) Methods
DE602007007958D1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties